PDF, Patent Landscape Report on Atazanavir - WIPO

More documents

Recommendations

Info

US CLASSIFICATION SYSTEMThe US classification system is much older than the International Classification Codes, andis organized quite differently. It is entirely numerical, and each Class has many divisionsthat are organized hierarchically, but the hierarchical numbering is not nested in the waythat the IPC codes are more likely to be. This means that the relatedness oneclass/subclass to another cannot be determined from the numbers themselves, but rathermust be investigated one by one using the code descriptions provided by the US <strong>Patent</strong>and Trademark Office.The most common US codes found in the chemical subcollection are shown in Figure 46.But the numbers after the class designation (first 3 digits), do not convey hierarchicalrelationships. The hierarchical relationships are solely conveyed by the level of indentationunder the primary US Class, as shown in Figure 47.Figure 46 US Codes found in the targeted Chemical CollectionFigure 47 Sample of the classification hierarchy for US Code 546/332Simple Example:52
DERWENT MANUAL CODESDWPI Manual Codes are the proprietary codes attached to Derwent abstracts byexperienced reviewers. They are available to subscribers of various search interfaces(Dialog, STN, Thomson Innovation). Figure 48 shows the DWPI Manual Codes appearingmost frequently in the precisely targeted collection. Those that are most specific arehighlighted. These codes are recognizably hierarchical, and tend to bring subjects of sharedinterest closer together in the hierarchy, for example the B07-D04B code on production ofcompounds is followed immediately by the B07-D04C code on use of the samecompounds. In this code system, a code for anti-retroviral (HIV) drugs was introduced at anearlier date than is the case for the IPC codes.Figure 48. Observed DWPI Manual Code Selection53
Page 4 and 5: ContentsSECTION 1: THE TWO OBJECTIV
Page 7 and 8: collection for nuggets of intellige
Page 9 and 10: CHEMICAL NAMINGChemical naming conv
Page 11 and 12: Figure 2: Legal Status for Novartis
Page 13 and 14: name, but after the patent protecti
Page 15 and 16: STAGE TWO CLINICAL SEARCHTo be more
Page 17 and 18: CLINICAL COLLECTIONThis is an examp
Page 19 and 20: THE FOUNDER PATENT AND ITS DOWNSTRE
Page 21 and 22: CHEMICAL COLLECTIONThis is an examp
Page 23 and 24: SECTION 5: GENERAL OVERVIEW OF THE
Page 25 and 26: FAMILY MEMBER COUNTRIESLooking at p
Page 27 and 28: The crossover between categories is
Page 29 and 30: THE DEVELOPER’S OWN TIMELINEThe A
Page 31 and 32: Several of the representative paten
Page 33 and 34: Figure 25. Emphasis Matrix for Sele
Page 35 and 36: PATENT QUALITY INDICATORS FOR SELEC
Page 37 and 38: Figure 30. References made by the F
Page 39 and 40: FORMULATIONSEven before a drug is a
Page 41 and 42: Figure 34. References to Bristol My
Page 43 and 44: PROPRIETARY DRUGS AND LITIGATIONThe
Page 45 and 46: TWO DRUGS DIRECTED AT THE SAME TARG
Page 47 and 48: Citations to this document mainly c
Page 49 and 50: USING OVERLAP TO FIND COMBINATIONS
Page 51 and 52: INTERNATIONAL PATENT CLASSIFICATION
Page 53: ased on the IPC, but with sometimes
Page 58: For more information contact WIPO a

PDF, Patent Landscape Report on Atazanavir - WIPO

Create successful ePaper yourself

Delete template?

Save as template?